http://repub.eur.nl/res/aut/51384/ List of Publications en http://repub.eur.nl/static-eur/img/logo.png http://repub.eur.nl http://repub.eur.nl/res/pub/39688/ 2013-03-26T00:00:00Z Background and aims: Successful transfer of adolescent IBD patients to an adult gastroenterologist requires anticipation of a changing role for patients and their parents. Self-efficacy has been demonstrated to be important for transfer readiness. We therefore developed an IBD-specific questionnaire (the "IBD-yourself") to assess self-efficacy in adolescent IBD patients visiting a transition clinic. Our aim was to evaluate the reliability of this questionnaire, and to describe the self-efficacy level of adolescent IBD patients, and the perceived self-efficacy level according to their parents. Methods: In a cross-sectional design, 50 IBD patients (aged 14-18 years) and 40 parents completed the "IBD-yourself" questionnaire. Internal reliability was assessed by standardised Cronbach's α. Median self-efficacy scores per domain were calculated. Results: The domains of the questionnaire for adolescents showed good to excellent internal consistency, with Cronbach's α ranging from 0.64 to 0.93. The domains of the parental questionnaire had Cronbach's α ranging from 0.47 to 0.93. Median self-efficacy scores of adolescents varied from 70 to 100%. In comparison with patient's self-assessment, parents thought that their child was more self-efficacious in knowledge of IBD and diagnostic tests, self-management of medication use, and transfer readiness. Length of time since first visit to the transition clinic was positively correlated with several domains of the questionnaire, such as independent behaviour at the outpatient clinic, and transfer readiness. Conclusion: The "IBD-yourself" questionnaire is a first step toward evaluating quality and efficacy of IBD transition programmes. Paediatric gastroenterologists should be aware that parents do not always accurately assess the self-efficacy of their child. http://repub.eur.nl/res/pub/37166/ 2012-09-07T00:00:00Z The inflammatory bowel diseases (IBD) are chronic relapsing inflammatory disorders of the gastrointestinal tract, comprising Crohn’s disease (CD), ulcerative colitis (UC), and IBD-unclassified (IBD-U). CD is characterized by a transmural and often granulomatous inflammation that can involve any part of the gastrointestinal tract in a discontinuous manner, while UC is defined as a chronic inflammatory condition causing continuous mucosal inflammation of the colon, without granulomas on biopsy, affecting the rectum and a variable extent of the colon in continuity. The term IBD-U is used for patients presenting with IBD restricted to the colon without the specific features of either CD or UC.2 Early-onset IBD represents a distinct disease entity with differences in disease type, disease location, disease behavior, gender preponderance, and genetically attributable risk compared with late-onset IBD. As in adults, treatment of early-onset IBD is aimed at inducing and maintaining remission, but special considerations are needed regarding optimal growth, pubertal development, and the transition period to adult care. A better understanding of the differences between early-onset and late-onset IBD will eventually lead to a better understanding of the pathogenesis of the disease. One of the limitations of studying pediatric IBD is however that a relatively small number of patients is available for study at one institution, which requires ongoing collaborations between many institutions. This thesis will present six (inter)national multicenter studies, a single-center pilot study and a review, which all focus on the unique clinical aspects of pediatric IBD, thereby complementing the relatively small body of literature on the diagnosis and treatment of children with IBD. http://repub.eur.nl/res/pub/33791/ 2011-01-01T00:00:00Z Background Infliximab is effective for induction and maintenance of remission in children with moderately to severely active Crohn's disease (CD). Aim To evaluate the long-term efficacy of infliximab treatment in paediatric CD. Methods In this observational, multicentre study, all paediatric CD patients in The Netherlands treated with infliximab from October 1992 to November 2009 and with minimal follow-up of 3 months since start of infliximab, were studied. Results One hundred and fifty-two CD patients [81M; median age at start of infliximab 15.0 years (IQR 13.1-16.4)] received a median number of 10.5 infliximab infusions (IQR 6-21). Median follow-up after start of infliximab was 25 months (IQR 13-40). Kaplan-Meier analysis showed that the cumulative probability of losing response to infliximab in patients who initially required repeated infusions was 13%, 40% and 50% after 1, 3 and 5 years, respectively. Seventy-four patients (49%) needed dose adjustments, with a median time to any adjustment of 6 months. Conclusions Duration of effect of infliximab is limited as 50% of patients on infliximab maintenance treatment lose their therapeutic response after 5 years. Dose adjustments after start of infliximab are frequently needed to regain therapeutic benefit. These findings emphasise the need for effective, long-term treatment strategies for paediatric CD.